Study guide

5.3 Immunogenicity and Antigen Prevalence

Scientist in Blood Banking, BB ASCP

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility Routes and Application 1.3 CMP, Credential Citation, and BB vs SBB

2 Donors and Collection

2.1 Donor Qualification 2.2 Collection Methods and Adverse Reactions 2.3 Special Donations

3 Processing, Storage, and Component QC

3.1 Processing: FDA/AABB Requirements, Testing, and Labeling 3.2 Anticoagulants, Additives, and Storage Temperatures 3.3 Transportation, Stored-Product Properties, and Expiration 3.4 Blood Component Quality Control

4 Blood Components

4.1 Red Blood Cells, Whole Blood, Washed, Frozen, and Rejuvenated 4.2 Platelets, Plasma, and Cryoprecipitated AHF 4.3 Granulocytes, Leukoreduced, and Irradiated Components 4.4 Apheresis Products, Fractionation, and Hematopoietic Progenitors

5 Blood Group Genetics and Transfusion Role

5.1 Basic and Molecular Genetics 5.2 Inheritance of Blood Groups 5.3 Immunogenicity and Antigen Prevalence

6 ABO and Lewis Systems

6.1 ABO Biochemistry and Antigens 6.2 ABO Antibodies, Discrepancies, and Subgroups 6.3 Lewis System

7 Rh System

7.1 Rh Genetics and Antigens 7.2 Weak D, Partial D, and Rh Antibodies 7.3 Rh Phenotyping and Clinical Significance

8 Kell, Duffy, Kidd, and MNS

8.1 Kell System 8.2 Duffy System 8.3 Kidd System 8.4 MNS System

9 Additional Systems and Antigens

9.1 P1PK, Globoside, and Ii Systems 9.2 Lutheran and Other Blood Group Systems 9.3 High- and Low-Prevalence Antigens 9.4 HLA, Platelet-Specific, and Granulocyte-Specific Antigens

10 Immunology Foundations

10.1 Immune Response, B and T Cells, Macrophages 10.2 Immunoglobulins: Classes, Structure, and Properties 10.3 Antigen-Antibody Interactions and Testing 10.4 Complement Pathways and Biologic Properties

11 Physiology, Hemostasis, Cytopenias, and Transplantation

11.1 Physiology of Blood 11.2 Hemostasis and Coagulation 11.3 Immune and Nonimmune Cytopenias 11.4 Solid Organ and HPC Transplantation

12 Hemolytic Disease of the Fetus and Newborn

12.1 HDFN Pathophysiology 12.2 HDFN Detection 12.3 HDFN Treatment and Prevention

13 Routine Serologic Testing

13.1 Blood Grouping Tests 13.2 Antibody Detection 13.3 Compatibility Testing and Crossmatch 13.4 Direct Antiglobulin Testing

14 Antibody Identification

14.1 Antibody Identification and Rule-Out 14.2 Clinical Significance, Dosage, and Multiple Antibodies 14.3 Panel Problem-Solving and Common Traps

15 Reagents and Special Techniques

15.1 Antiglobulin Sera, Grouping Sera, and Reagent Red Cells 15.2 Enzymes, Enhancement Media, and Lectins 15.3 Adsorption, Elution, Titration, and Cell Separations 15.4 Molecular, Solid-Phase, Column, ELISA, and Related Methods

16 Serologic QA and Special Reagents

16.1 Blood Sample Quality Assurance 16.2 Reagent and Procedure Quality Assurance 16.3 Thiol Reagents, Neutralization, Chloroquine, EGA, and Immunofluorescence

17 Indications and Component Therapy

17.1 Indications for Transfusion 17.2 Red Cell and Whole Blood Therapy 17.3 Platelet, Plasma, and Cryoprecipitate Therapy 17.4 Special Component Therapy

18 Adverse Effects of Transfusion

18.1 Immunologic Transfusion Reactions 18.2 Nonimmunologic Transfusion Reactions 18.3 Transfusion-Transmitted Diseases

19 Apheresis, Administration, and Patient Blood Management

19.1 Apheresis and Extracorporeal Circulation 19.2 Blood Administration 19.3 Patient Blood Management

20 Laboratory Operations

20.1 Quality Assessment and Troubleshooting 20.2 Quality Control, Proficiency Testing, and Regulation 20.3 Laboratory Safety 20.4 Laboratory Mathematics and Instrumentation

5.3 Immunogenicity and Antigen Prevalence

Key Takeaways Explain This Topic AI

After ABO, D is the most immunogenic red-cell antigen. Classic ranking: D >> K > c > E > k, Fya, Jka, S. Immunogenicity is not the same as antigen frequency.

Antigen frequencies differ by ancestry (D 85/92/99, C 70/27/93, K 9/2/<0.1, Fya 66/10/99 percent in European / African / East Asian columns). Never apply the Caucasian column to every patient.

Fy(a−b−) is common in African ancestry because a GATA-1 erythroid promoter mutation silences FYB on red cells only; tissues still express Fyb (usually no anti-Fyb) and P. vivax invasion is reduced.

High-prevalence antigen-negative units (k, Kpb, Jsb, U, Vel) are rare-donor problems, not refrigerator hunts. Units to screen = n / product of ancestry-correct negative frequencies.

Lewis antibodies are usually not clinically significant (typically IgM, not 37 °C/AHG, no HDFN). Do not reflex Le(a−b−) units.

Last updated: August 2026

5.3 Immunogenicity and Antigen Prevalence

Quick Answer: After ABO, D is the most immunogenic red-cell antigen. The classic ranking is D >> K > c > E > k, Fya, Jka, S . Antigen frequencies differ by ancestry — never use the Caucasian column for every patient . Fy(a−b−) is common in African ancestry because a GATA-1 promoter mutation silences FY B on red cells only (tissues still express Fyb; malaria P. vivax resistance). High-prevalence antigen-negative units are rare and come from rare-donor files. Lewis antibodies are usually not clinically significant — do not reflex Le(a−b−) units.

Immunogenicity is not the same as frequency

Immunogenicity is the probability that an antigen-negative person will form an alloantibody after exposure. Frequency is how often the antigen appears in a population. K is uncommon (~9% of European-ancestry donors) and highly immunogenic . Antigen e is almost universal and weakly immunogenic. Mixing those ideas produces the wrong antibody to expect after a unit of e+ blood. Outline II.C (June 9, 2026) tests both the ranking and the ancestry table.

Classic ranking the BB exam still uses (protein antigens, after ABO incompatibility):

D >> K > c > E > k, Fya, Jka, S (then C, e, and the rest).

Numbers worth an item: historically, about 80% of D− recipients of a full D+ red-cell unit formed anti-D (modern leukoreduced, shared-decision practice is lower, but “D is in a class by itself” is unchanged). K immunizes on the order of 10% of exposed K− recipients — far above Duffy or Kidd. That is why K is in every prenatal panel conversation and why many programs prophylactically match K for girls and women of childbearing potential even before an antibody appears. c and E are the next Rh troublemakers; anti-e and anti-C are less common because almost everyone is e+ and because C is less immunogenic than c. Jka is moderately immunogenic and infamous for disappearing from the screen, then causing a delayed hemolytic or delayed serologic transfusion reaction . S and Fya sit in the same “clinically significant, not D/K-level” band.

ABO remains outside this list because anti-A and anti-B are naturally occurring . You do not need a transfusion to make them. D, K, and Jka require exposure (transfusion or pregnancy), with rare “naturally occurring” exceptions the exam will flag as unusual.

Antigen frequencies you must not flatten into one U.S. number

Approximate percent antigen-positive values the exam expects (adults; rounded textbook figures):

  • Antigen European ancestry African ancestry East Asian ancestry
  • D 85 92 99
  • C 70 27 93
  • c 80 96 47
  • E 30 22 39
  • e 98 98 96
  • K 9 2 <0.1
  • k 99.8 >99 >99.9
  • Fya 66 10 99
  • Fyb 83 23 ~18
  • Fy(a−b−) rare ~68 rare
  • Jka 77 92 72
  • Jkb 74 49 76
  • M 78 74 80
  • N 72 75 73
  • S 55 31 89
  • s 89 93 ~100
  • Lea 22 23 23
  • Leb 72 55 73

Read the table as a decision tool, not trivia. A D− unit is uncommon in East Asian donors (~1%) and merely uncommon in European donors (~15%). A C− unit is easy to find in African-ancestry inventory and hard to find in East Asian inventory. K− is the default Asian unit and still 91% of European units. Fy(a−b−) is an African-ancestry phenotype, not a typing error. s− (often U-var or U− in African ancestry when S−s−) is a rare-donor problem, not a European-panel problem.

Why Fy(a−b−) exists — GATA-1, tissues, malaria

The common African FY-null RBC phenotype is not a deleted Duffy gene. It is a point mutation in the GATA-1 erythroid promoter of ACKR1 (T>C at the GATA motif, classically on the FY B allele). Erythroid transcription factor GATA-1 can no longer bind, so red cells make no Duffy . Non-erythroid tissues still transcribe FY B, so the person expresses Fyb on endothelium . Consequences the exam loves:

Red cells type Fy(a−b−) .

The patient can make anti-Fya if exposed to Fya (they have no Fya anywhere).

The patient usually does not make anti-Fyb , because tissues display Fyb — it is “self.”

A microarray that reads only the 125G>A Fya/Fyb SNP will call FYB / Fyb+ unless the assay also targets the GATA-1 promoter SNP.

Duffy on red cells is the receptor for Plasmodium vivax (and P. knowlesi ). The silenced erythroid phenotype is the human adaptation that reduces P. vivax invasion. It is not protection against P. falciparum .

Do not issue Fy(b−) blood as a standing order for every Fy(a−b−) African-ancestry patient “just in case.” Match for Fya if they have anti-Fya. Do not invent anti-Fyb they have not made. True FY gene deletion (rare) can make anti-Fy3; the common GATA-1 African phenotype does not behave that way.

High-prevalence antigens and the rare unit

k, Kpb, Jsb, U, Vel, Yta, Coa, Ge, Lub, Kx are high-prevalence : >99% of unselected donors are positive. The antigen-negative unit is rare . You will not find two k− units by screening the 20 O-negative walk-in units in the refrigerator. Those requests go to a rare donor registry , autologous donation, siblings (25% chance of the same recessive-looking null if both parents are heterozygotes), or — when clinically justified — least-incompatible blood plus medical-director approval. Jsb− is more often found in African-ancestry donors; Kpb− is not. Searching the wrong ethnic donor file wastes the night.

Selecting antigen-negative blood and calculating the screen

Once the antibody is identified and is clinically significant (reactive at 37 °C / AHG, associated with HDFN or hemolytic transfusion reactions):

Type the patient for the corresponding antigen — they should be negative.

Crossmatch antigen-negative units. For multiple antibodies, the unit must be negative for every implicated antigen.

Calculate how many units to pull for typing: n / (product of antigen-negative frequencies in the correct population) .

Example: African-ancestry patient with anti-E and anti-C. C− ≈ 73% (1 − 0.27), E− ≈ 78% (1 − 0.22). Combined 0.73 × 0.78 ≈ 0.57. Two units: 2 / 0.57 ≈ 4 units to screen. If you wrongly used European frequencies (C− 30%, E− 70% → 0.21), you would tell the floor you need 10 units and delay a surgery that four typed units would have covered.

Give prophylactic extended matching (C, c, E, K, and often Jka, Fya) to sickle-cell and other chronically transfused patients before they make the antibody — that is prevalence plus immunogenicity used as prevention.

Traps that cost points

Using Caucasian frequencies for all patients. An African-ancestry patient needing Fy(a−) blood is easy (only ~10% are Fya+). A European-ancestry patient needing Fy(a−) is not (~34% Fya−). The reverse is true for c− units.

Calling Lewis clinically significant. Anti-Lea and anti-Leb are typically IgM , often naturally occurring, and usually do not react at 37 °C / AHG . They do not cause HDFN (Lewis antigens are adsorbed, poorly developed at birth, and the antibodies do not cross the placenta as IgG). You do not routinely provide Le(a−b−) units. Neutralization with saliva or a 37 °C screen that is negative lets you ignore them. Rare AHG-reactive Lewis antibodies exist; the default exam answer is still “not clinically significant.”

Confusing immunogenicity with prevalence. “Everyone is e+, so anti-e must be common” is backwards. “K is rare, so anti-K must be rare” is also backwards — K is uncommon and very immunogenic, and anti-K is one of the most frequent immune antibodies after ABO and D.

Treating Fy(a−b−) as a Duffy-null person who will routinely make anti-Fy3 or anti-Fyb. The common GATA-1 African phenotype does not.

Screening the refrigerator for k− or U− units. High-prevalence-negative blood is a rare-donor problem.

Loading diagram... Antigen-negative unit selection: immunogenicity, ancestry, Lewis trap